# Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine

> **NCT02639351** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 80 (actual)

## Conditions studied

- Infections, Meningococcal

## Interventions

- **BIOLOGICAL:** Investigational MenC-CRM adjuavnted with 12.5 ug of LHD153R
- **BIOLOGICAL:** Investigational MenC-CRM adjuavnted with 25 ug of LHD153R
- **BIOLOGICAL:** Investigational MenC-CRM adjuavnted with 50 ug of LHD153R
- **BIOLOGICAL:** Investigational MenC-CRM adjuavnted with 100 ug of LHD153R
- **BIOLOGICAL:** Meningococcal C-CRM Conjugate Vaccine (MenC-CRM)

## Key facts

- **NCT ID:** NCT02639351
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-01
- **Primary completion:** 2017-08-31
- **Final completion:** 2017-08-31
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2019-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02639351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02639351, "Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02639351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*